Longitude Cayman Ltd. Reduces Stock Position in Amarin Co. plc (NASDAQ:AMRN)

Longitude Cayman Ltd. decreased its stake in Amarin Co. plc (NASDAQ:AMRN) by 31.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,620,000 shares of the biopharmaceutical company’s stock after selling 750,000 shares during the quarter. Longitude Cayman Ltd.’s holdings in Amarin were worth $786,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in AMRN. Arkfeld Wealth Strategies L.L.C. boosted its stake in shares of Amarin by 52.6% in the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 20,000 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Amarin by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 29,992 shares during the period. Kornitzer Capital Management Inc. KS boosted its position in Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 42,700 shares during the period. LCM Capital Management Inc boosted its position in Amarin by 3.1% during the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 25,100 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after buying an additional 104,939 shares during the period. Hedge funds and other institutional investors own 22.25% of the company’s stock.

Amarin Stock Down 3.3 %

Shares of AMRN opened at $0.52 on Tuesday. The stock has a market capitalization of $214.94 million, a P/E ratio of -5.82 and a beta of 1.83. The firm has a fifty day simple moving average of $0.52 and a two-hundred day simple moving average of $0.57. Amarin Co. plc has a twelve month low of $0.43 and a twelve month high of $1.36.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Amarin from a “hold” rating to a “sell” rating in a research report on Friday, January 24th.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.